Health Trials

Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction

ConditionsHeart FailurePreserved Ejection Fraction
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBoehringer Ingelheim

About this trial

The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.

Eligibility criteria

Qualifiers

At least 18 years of age

At least 6 months of data prior to the index date

Left ventricular ejection fraction (LVEF) > 40 %

N-terminal Pro-B-type natriuretic peptide (NT-proBNP) > 125 pg/mL or brain natriuretic peptide (BNP) ≥ 35 pg/mL

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

3,000 Participants
are grouped into 1 trial group

Locations

This trial has no locations

Sponsors and collaborators

Boehringer Ingelheim

Lead sponsor

Source ClinicalTrials.gov